Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Azra Raza, MD, Benjamin Tycko, M.D., Ph.D., Sangmin Lee, MD, Naomi Galili, Ph.D., Abdullah Ali, Andrew Eisenberger, MD, John G. Mears, MD, Aref Al-Kali, MD, Raoul Tibes, MD, PhD, Gary Spitzer, MD, Francois Wilhelm, MD, PhD., Siddhartha Mukherjee, MD, PhD

Blood (2013) 122 (21): 2745.

https://doi.org/10.1182/blood.V122.21.2745.2745

Published: 2013

Journal Articles

Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML)

Naomi Galili, Ph.D., Vladimir Trifonov, PhD, Mark Ewalt, MD, Siddhartha Mukherjee, MD, PhD, Raul Rabadan, Azra Raza, MD

Blood (2012) 120 (21): 169.

https://doi.org/10.1182/blood.V120.21.169.169

Published: 2012

Journal Articles

Activity of Lenalidomide in a Phase II Single Institution Study in Non-Del(5q) Transfusion Dependent, Patients with Low and Intermediate-1 Risklower-Risk, Non-Del(5q) Myelodysplastic Syndromes (MDS))): Results From a Single-Institution Phase II Study

Azra Raza, MD, John Falkenstern, Fiona Yeh, Ginevra Castagna, Antonietta De Los Reyes, Naomi Galili, Ph.D.

Blood (2012) 120 (21): 4929.

https://doi.org/10.1182/blood.V120.21.4929.4929

Published: 2012

Journal Articles

Survival Analysis of Myelodysplastic Syndrome (MDS) Patients with Abnormal Karyotype - A Single Group Experience

Muhammad Nadeem, MD, Naomi Galili, Ph.D., Muhammad Mumtaz, Peter Daya, Jason Cheskis, Azra Raza, MD

Blood (2012) 120 (21): 4952.

https://doi.org/10.1182/blood.V120.21.4952.4952

Published: 2012

Journal Articles

The Clinical and Biologic Significance of Thrombocytosis in Myeloid Disorders

Jennifer Zikria, MD, Naomi Galili, Ph.D., Wei Yann Tsai, PhD, Azra Raza, MD

Blood (2011) 118 (21): 5031.

https://doi.org/10.1182/blood.V118.21.5031.5031

Published: 2011

Journal Articles

Validation of a Prognostic Model and the Impact of SF3B1 , DNMT3A , and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples

Rafael Bejar, MD, PhD, Kristen Stevenson, Bennett Caughey, Omar Abdel-Wahab, MD, Naomi Galili, Ph.D., Guillermo Garcia-Manero, Hagop M Kantarjian, Azra Raza, MD, David P. Steensma, MD, Ross L Levine, MD, Donna Neuberg, ScD, Benjamin L. Ebert, MD, D.Phil

Blood (2011) 118 (21): 969.

https://doi.org/10.1182/blood.V118.21.969.969

Published: 2011

Journal Articles

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Deborah Mulford, MD, Scott E. Smith, MD, PhD, FACP, Gail Brown, MD, Lisa Meng, PhD, David P. Steensma, MD, Roger M. Lyons, MD, Ralph Boccia, MD, Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, Ruben A. Mesa, MD

Blood (2011) 118 (21): 2778.

https://doi.org/10.1182/blood.V118.21.2778.2778

Published: 2011

Journal Articles

Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199)

Naomi Galili, Ph.D., Pablo Tamayo, PhD, Olga B Botvinnik, Jill P Mesirov, PhD, Jennifer Zikria, MD, Gail Brown, MD, Azra Raza, MD

Blood (2011) 118 (21): 2779.

https://doi.org/10.1182/blood.V118.21.2779.2779

Published: 2011

Journal Articles

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Scott Smith, MD, PhD, FACP, John E. Godwin, MD, MS, Ralph Boccia, MD, Han Myint, MD, Daruka Mahadevan, MD, PhD, Deborah Mulford, MD, Mark Rarick, MD, Mary Ann Allison, MD, Ostap Melnyk, MD, Lisa Meng, Marsha Jones, MD, Gail Brown, MD, Shelby A Young, RN, BSN, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 2910.

https://doi.org/10.1182/blood.V116.21.2910.2910

Published: 2010

Journal Articles

Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival

Rafael Bejar, MD, PhD, Kristen Stevenson, Omar Abdel-Wahab, MD, McConkey Marie, PhD, Katherine Lin, James Randall McAuley, Kevin Cheung, MD, Naomi Galili, Ph.D., Guillermo Garcia-Manero, MD, Hagop Kantarjian, MD, Azra Raza, MD, Ross Levine, MD, Donna Neuberg, ScD, Benjamin L. Ebert, MD, DPhil

Blood (2010) 116 (21): 300.

https://doi.org/10.1182/blood.V116.21.300.300

Published: 2010

Journal Articles

Thrombocytopenia Predicts for Poor Survival In Patients with Lower Risk Myelodysplastic Syndromes (MDS)

Raymond Cruz, MD, Naomi Galili, Ph.D., Ghulam Sajjad Khan, MD, Azra Raza, MD

Blood (2010) 116 (21): 4021.

https://doi.org/10.1182/blood.V116.21.4021.4021

Published: 2010

Journal Articles

Arsenic Trioxide (Trisenox®) with/without Thalidomide in Patients with Myelodysplastic Syndromes (MDS) Produces Hematologic Improvement (HI).

Azra Raza, M.D, Laurie Lisak, P.A.C, Jennifer Billmeier, P.A.C, Samreen Akbar, M.D, Khalid Washeed, M.D, Mohammad Mumtaz, B.A, Poluru Reddy, Ph.D, Naomi Galili, Ph.D

Blood (2004) 104 (11): 4710.

https://doi.org/10.1182/blood.V104.11.4710.4710

Published: 2004

NARROW

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML)

Activity of Lenalidomide in a Phase II Single Institution Study in Non-Del(5q) Transfusion Dependent, Patients with Low and Intermediate-1 Risklower-Risk, Non-Del(5q) Myelodysplastic Syndromes (MDS))): Results From a Single-Institution Phase II Study

Survival Analysis of Myelodysplastic Syndrome (MDS) Patients with Abnormal Karyotype - A Single Group Experience

The Clinical and Biologic Significance of Thrombocytosis in Myeloid Disorders

Validation of a Prognostic Model and the Impact of SF3B1 , DNMT3A , and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199)

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival

Thrombocytopenia Predicts for Poor Survival In Patients with Lower Risk Myelodysplastic Syndromes (MDS)

Arsenic Trioxide (Trisenox®) with/without Thalidomide in Patients with Myelodysplastic Syndromes (MDS) Produces Hematologic Improvement (HI).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only